---
title: "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer"
description: "This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib"
url: "https://www.clareohealth.com/clinical-trials/NCT00404066"
---

This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast cancer. The purpose of the study was to determine whether lapatinib combined with chemotherapy was safe and resulted in an increase in pathologic complete response rates.

## Key Facts

**ID:** NCT00404066
**Status:** COMPLETED
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 21
**Sponsor:** George Albert Fisher

## Detailed Description

Lapatinib acts as a dual inhibitor of both epidermal growth factor receptor (EGFR) and ErbB-2 (Her2/neu) tyrosine kinase activity. EGFR and ErbB2 receptors are frequently over-expressed or altered in human cancers including breast cancer. This study plans to determine the antitumor activity of this regimen and its effectiveness preventing tumor growth and spread. Neoadjuvant chemotherapy which achieves pathologic complete responses (pCR) has been shown to predict improved long-term survival and serves as a surrogate for clinical outcome. By using this primary endpoint we can obtain statistical data with smaller patient numbers and at a lower overall cost. Additionally, we hope to correlate clinical and radiologic outcomes with gene expression data.

## Conditions

- Breast Cancer
- Metastatic Breast Cancer

## Interventions

**DRUG: Lapatinib**
1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)

**DRUG: Doxorubicin**
60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.

**DRUG: Cyclophosphamide**
600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.

**DRUG: Docetaxel**
100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide

**DRUG: Pegfilgrastim**
6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.

**DRUG: Filgrastim**
300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.

**DRUG: Dexamethasone**
8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel

**DRUG: Trastuzumab**
Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year

## Eligibility

INCLUSION CRITERIA * Female * Histologically-confirmed Her2neu positive breast cancer, by either Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization (FISH)+ * Stag…

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 70

**Sex:** FEMALE

**Accepts healthy volunteers:** No

## Study Locations

- Santa Clara Valley Medical Center, San Jose, California, United States
- Stanford University School of Medicine, Stanford, California, United States

## Contact Information

## Important Dates

**Study start:** October 1, 2006

**Completion date:** March 1, 2011

**Last updated:** December 22, 2017

## Collaborators

- GlaxoSmithKline
- Sanofi

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00404066)
